MSLE – satellos bioscience inc. (US:NASDAQ)

News

Satellos Bioscience (MSLE) is now covered by Guggenheim. They set a "buy" rating and a $23.00 price target on the stock.
Satellos Bioscience (MSLE) was downgraded by Wall Street Zen from "se
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
Satellos Bioscience (MSLE) is now covered by Leerink Partners. They set an "outperform" rating and a $20.00 price target on the stock.
Satellos Bioscience (MSLE) had its price target raised by HC Wainwright from $1.20 to $11.00. They now have a "buy" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com